ANKRD13D

Across TCGA pan-cancer cohorts, ANKRD13D mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ANKRD13D data layer compared with 21 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ANKRD13D mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ANKRD13D expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

PDAC, HNSC, and LSCC are the cancer types where ANKRD13D mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	III,IV	0.391	0.879	<.001	53	view →
HNSC	DFS	Tertile	III,IV	1.000	0.867	.016	10	view →
LSCC	DFS	Median	II,III,IV	0.653	0.897	.003	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ANKRD13D–PDAC (OS)

Open the PDAC breakdown →